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Abstract
Determining the HER2 status of breast
carcinomas is a prerequisite for the use of
the monoclonal antibody trastuzumab
(Herceptin®), which has recently been
licensed for the treatment of metastatic
disease. This necessitates a test based on
archival material. The preferred analyses
are immunohistochemistry with fluores-
cent in situ hybridisation (FISH) as a fol-
low up test for ambiguous results.
Guidelines have been developed for stand-
ardised, well controlled procedures for the
provision of reliable results. A group of
three reference laboratories has been
established to provide advice, quality
assurance, and materials, where needed.
(J Clin Pathol 2000;53:890–892)
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The humanised anti-HER-2/neu (also known
as c-erbB-2, further denoted HER2) mono-
clonal antibody trastuzumab (Herceptin®) can
be used to treat women with HER2 positive
metastatic breast cancer.1 Establishing tumour
HER2 status is a prerequisite for the use of
trastuzumab.2 However, a widely accepted and
standardised test for HER2 status is not
currently available.3 These recommendations
have been designed to give notice of the avail-
ability of a reference laboratory service and to
give advice on methodology for local testing to
ensure that HER2 testing results are accurate
and reliable, regardless of the test that is used.
General principles
SUITABLE SAMPLES
Formalin fixed, paraYn wax embedded
tumour tissue samples are appropriate for
assay.4 Other methods of tissue fixation can
adversely aVect reactivity.
APPROPRIATE LABORATORY ASSAY METHODS
Immunohistochemistry (IHC) and fluorescent
in situ hybridisation (FISH)5 are the tech-
niques recommended for determining HER2
status. We do not intend to be prescriptive
about methodology or the antibodies suitable
for ICH because there is no substantive
evidence to support the exclusive use of one
IHC testing method or reagent. For immuno-
histochemical HER2 testing, comprehensive
standardisation of methodology and the inclu-
sion of validated controls are mandatory. The
HercepTest® meets these criteria, but owing to
cost considerations, other IHC tests and
antibodies other than the polyclonal antiserum
used in this test may be used (see recommen-
dations regarding the use of controls and test
validation below).
FISH testing for HER2 should meet the fol-
lowing criteria: (1) the inclusion of a chromo-
some 17 control to allow for correction of the
HER2 signal number for chromosome 17
aneusomy (seen in over 50% of cases); (2)
comprehensive standardisation of method-
ology; and (3) validated controls. Although
there are several commercial systems available
for FISH HER2 testing, the PathVysion™ assay
(Vysis, Richmond, Surrey, UK) is recom-
mended for diagnostic testing because it meets
the above criteria. Owing to cost considera-
tions, other probes and in house prepared
probes may be use, but care must be taken to
ensure that these are correctly validated (see
recommendations below).
Currently, the other available HER2 testing
techniques (polymerase chain reaction, enzyme
linked immunosorbent assay, Southern blot-
ting) should be used for research only.
Standard protocols should be developed and
applied for local IHC or FISH HER2 tests.
These should be validated using standardised
commercial kit assays or local assay method-
ologies that have been validated against the well
characterised tissue sets that are available from
the reference laboratories (see below).
CONTROLS
The inclusion of controls of known HER2 sta-
tus in all HER2 tests is required to ensure test
accuracy. One positive and one negative
control of known immunoreactivity and gene
signal number are recommended as a mini-
mum; controls producing results close to
important decision making points should also
be considered.
The reference laboratories can validate
locally produced controls by FISH and Her-
cepTest if required.
Tissue array blocks containing multiple
tissue samples of known HER2 status charac-
terised by FISH and IHC are being developed
by the reference laboratories to facilitate test
validation.
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Immunohistochemistry
FOR ALL IHC TESTS
Antigen retrieval processes should be standard-
ised and follow strict protocols. The antibody
used and its titre should be predefined. No sin-
gle antibody has been consistently demon-
strated to be superior in terms of specificity and
sensitivity. At present, antibodies CB11 (Novo-
castra, Newcastle Upon Tyne, UK), TAB 250
(Zymed, San Francisco, California, USA), and
A0485 (Dako, Ely, Cambridgeshire, UK) are
the most widely used. Test conditions (tem-
perature, exposure time, etc) should be stand-
ardised.
There is evidence that HER2 protein reactiv-
ity may deteriorate in fixed paraYn wax
sections over a period of months. It is
recommended that control block sections are
prepared fresh or that storage time is restricted
to < 3 months unless testing to assess degrada-
tion has been conducted.
Test conditions should be optimised so that
distinct moderate or strong membrane staining
identifies FISH positive samples.
Laboratories not wishing to standardise in
house methodology should consider using a
commercial kit assay system such as the
HercepTest.
Excessive antigen retrieval can be monitored
by an evaluation of normal breast epithelial
cells as an internal control. Should membrane
reactivity be identified in the normal cell popu-
lation, excessive antigen retrieval may have
occurred. It is recommended that the assay be
rejected and retested. Alternatively, some
groups have recommended that scoring of the
tumour cell population be modified by sub-
tracting the degree of normal cell reactivity.
SCORING IHC
Only membrane staining of the invasive
tumour should be considered when scoring
IHC tests.
If the HercepTest is used, it is recommended
that laboratories adhere strictly to the kit assay
protocol and scoring methodology. Local
modifications of techniques can lead to false
positive and negative assay results. The scoring
method provided with the kit uses a semi-
quantitative system based on the intensity and
percentage of positive cells, giving a score range
of 0 to 3+. Samples scoring 3+ are regarded as
unequivocally positive and 0/1+ as negative.
Borderline 1+/2+ and 2+ require confirmation
using another analysis system, preferably
FISH.
Until there is more evidence based on
patient response to treatment, we recommend
using the HercepTest scoring method for
tumours assessed using other IHC methods.
We anticipate that simplified IHC scoring
methods will be developed. For example, cases
should be reported as positive for HER2 over-
expression if > 10% of cells show moderate or
strong complete membrane staining; cases that
show equivocal/borderline reactivity should be
retested, preferably using FISH.
Interobserver variation in the assessment of
staining can lead to misclassification of HER2
status. Each individual should standardise
scoring against known positive, negative, and
borderline cases.
QUALITY ASSURANCE
Laboratories oVering an IHC service are
advised to participate in the UK NEQAS
Immunohistochemistry External Quality As-
surance (EQA) scheme.
Fluorescence in situ hybridisation (FISH)
The Vysis PathVysion kit is recommended if
FISH is performed because it meets the above
mentioned criteria for proper HER2 FISH
testing, with results being expressed as the ratio
of HER2 signal to chromosome 17 signal.
Tumours showing a ratio of > 2 should be con-
sidered positive. Cut oV values for HER2 gene
amplification when chromosome 17 probes are
not used have not been established.
FOR ALL FISH TESTS
There is no evidence that storage of blocks or
slides leads to deterioration of signal. However,
storage of cut sections from controls or samples
for over six to 12 months should be avoided.
It is advisable to locate areas of invasive
tumour using a serial section stained with hae-
matoxylin and eosin and to use this to locate
tumour areas to be scored after testing. Care
should be taken to avoid areas of ductal carci-
noma in situ, which can show amplification
even where adjacent invasive tumour cells are
negative.
Tissue digestion should be standardised to
maintain nuclear morphology and should
follow strict protocols. Nuclear structure
should be evaluated before hybridisation and
digestion, where appropriate, to preserve nu-
clear integrity. Hybridisation and washing steps
should be standardised. Guidance can be pro-
vided by the reference laboratories.
It is recommended that commercially avail-
able probes are used. For systems using in
house nick translated probes, attention should
be given to batch variability of nick translation
enzymes, etc.
Laboratories not wishing to use in house
methods should consider using a commercial
system such as the Vysis PathVysion kit.
SCORING FISH
For all test systems, the scoring protocol
included in the PathVysion kit is recom-
mended. The number of chromosome 17 and
HER2 signals is scored for 60 cells, where pos-
sible from three distinct tumour fields, and the
mean HER2 to chromosome 17 copy ratio is
calculated. Where tumour heterogeneity is
seen (1–2% of cases), more cells from the
amplified regions should be scored. Samples
with > 2.0 copies of HER2 for each chromo-
some 17 are considered to be amplified.
Interobserver variation should be assessed
until good reproducibility is attained. For non-
amplified samples, interobserver variation
should be between 10% and 15%. Variation
increases with highly amplified samples, but is
not critical where the ratio exceeds 4.
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QUALITY ASSURANCE
To ensure adequate quality assurance, UK
laboratories wishing to set up independent
FISH testing are recommended to join the ref-
erence laboratories’ EQA scheme.
Reference laboratory service
For the UK, three HER2 testing reference
laboratories have been established in London,
Nottingham, and Glasgow.
+ Professor Mitch Dowsett, Department of
Biochemistry, The Royal Marsden Hospital,
Fulham Road, London SW3 6JJ, UK.
+ Dr Ian Ellis, Department of Histopathol-
ogy, City Hospital, Hucknall Road, Notting-
ham NG5 1PB, UK.
+ Dr John Bartlett, University Department
of Surgery, Glasgow Royal Infirmary, Level II,
Queen Elizabeth Building, Alexandra Parade,
Glasgow G31 2ER, UK.
These laboratories use validated IHC (Her-
cepTest) and FISH techniques (PathVysion) to
establish HER2 status, and also run an
interlaboratory quality assurance scheme.
The service provided by the reference
laboratories is available to all laboratories for
advice and testing of HER2 status.
Test results will be provided within two
weeks of sending to the reference laboratories.
Laboratories that require data sooner or have
in house procedures should conduct their test-
ing according to the above guidelines.
Similar initiatives are expected in other
countries where trastuzumab treatment is
used.
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